elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q37285551-749F5407-C2ED-4405-A1FE-A3CA114E1DEC
Q37285551-749F5407-C2ED-4405-A1FE-A3CA114E1DEC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37285551-749F5407-C2ED-4405-A1FE-A3CA114E1DEC
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
P2860
Q37285551-749F5407-C2ED-4405-A1FE-A3CA114E1DEC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37285551-749F5407-C2ED-4405-A1FE-A3CA114E1DEC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f2fe9faf42bc3979f44db6f1430b3d9613f8182f
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.